key: cord-0760951-5uwkfpom authors: Kijima, Yu; Shimizu, Tomokazu; Sekido, Eri; Kato, Shinya; Kano, Kana; Toguchi, Makoto; Horiuchi, Toshihide; Nozaki, Taiji; Omoto, Kazuya; Inui, Masashi; Toma, Hiroshi; Iida, Shoichi; Takagi, Toshio title: Allogeneic kidney transplantation after COVID-19: A case report date: 2021-10-15 journal: Transplant Proc DOI: 10.1016/j.transproceed.2021.10.004 sha: 3e92fac85a6a979d0ba32a09eafb1ab0dc55c79c doc_id: 760951 cord_uid: 5uwkfpom Background Patients undergoing organ transplantation are immunosuppressed and already at risk of various diseases. We report about a patient who underwent ABO-incompatible kidney transplantation following coronavirus disease (COVID-19) without a recurrence of infection. Case report A 68-year-old woman presented with end-stage renal failure due to primary autosomal dominant polycystic kidney disease; accordingly, hemodialysis was initiated in September 2020. Her medical history included bilateral osteoarthritis, lumbar spinal stenosis, hypertension, and hyperuricemia. In mid-January 2021, she contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from her husband. Both of them were hospitalized and received conservative treatment. Since their symptoms were mild, they were discharged after 10 days. The patient subsequently underwent ABO-incompatible kidney transplantation from her husband who recovered from COVID-19 in March 2021. Before kidney transplantation, her COVID-19 polymerase chain reaction test was negative, confirming the absence of pre-existing COVID-19 immediately before the procedure. Computed tomography revealed no pneumonia. Initial immunosuppression was induced by administering tacrolimus, mycophenolate mofetil, methylprednisolone, basiliximab, rituximab, and 30 g intravenous immunoglobulin. Double-filtration plasmapheresis and plasma exchange were performed once before ABO-incompatible kidney transplantation. The renal allograft functioned immediately, and the postoperative course was normal without rejection. COVID-19 did not recur. In addition, her serum creatinine levels and renal function had otherwise remained stable. Conclusion Living kidney transplantation was safely performed in a patient with COVID-19 without postoperative complications or rejection. During the COVID-19 pandemic, the possibility of SARS-CoV-2 infection during transplantation surgery must be considered. initiated in September 2020. Her medical history included bilateral osteoarthritis, lumbar spinal stenosis, hypertension, and hyperuricemia. In mid-January 2021, she contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from her husband. Both of them were hospitalized and received conservative treatment. Since their symptoms were mild, they were discharged after 10 days. The patient subsequently underwent ABO-incompatible kidney transplantation from her husband who recovered from COVID-19 in March 2021. Before kidney transplantation, her COVID-19 polymerase chain reaction test was negative, confirming the absence of pre-existing COVID-19 immediately before the procedure. Computed tomography revealed no pneumonia. Initial immunosuppression was induced by administering tacrolimus, mycophenolate mofetil, methylprednisolone, basiliximab, rituximab, and 30 g intravenous immunoglobulin. Double-filtration plasmapheresis and plasma exchange were performed once before ABO-incompatible kidney transplantation. The renal allograft functioned immediately, and the postoperative course was normal without rejection. COVID-19 did not recur. In addition, her serum creatinine levels and renal function had otherwise remained stable. Living kidney transplantation was safely performed in a patient with COVID-19 without postoperative complications or rejection. During the COVID-19 pandemic, the possibility of SARS-CoV-2 infection during transplantation surgery must be considered. Patients undergoing organ transplantation are immunosuppressed and already at risk of various diseases. We report about a patient who underwent ABO-incompatible kidney transplantation following coronavirus disease (COVID-19) without a recurrence of infection. A 68-year-old woman presented with end-stage renal failure due to primary autosomal dominant polycystic kidney disease; accordingly, hemodialysis was initiated in September 2020. Her medical history included bilateral osteoarthritis, lumbar spinal stenosis, hypertension, and hyperuricemia. In mid-January 2021, she contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from her husband, and both of them were hospitalized and received conservative treatment. Since their symptoms were mild, they were discharged after 10 days. The patient subsequently underwent ABO-incompatible kidney transplantation from her husband who recovered from COVID-19 in March 2021. Before kidney transplantation, she had a negative COVID-19 polymerase chain reaction (PCR) test result, confirming the absence of pre-existing COVID-19 immediately before the procedure. Computed tomography revealed no pneumonia. Immunosuppression was induced by administering tacrolimus, mycophenolate mofetil, methylprednisolone, basiliximab, rituximab, and 30 g intravenous immunoglobulin (Ig). Double-filtration plasmapheresis and plasma exchange were performed once before the ABO-incompatible kidney transplantation. The renal allograft functioned immediately, and the postoperative course was uneventful, without rejection (Fig. 1) . COVID-19 did not recur; moreover, her serum creatinine levels and renal function had otherwise remained stable. This was a rare case of kidney transplantation after SARS-CoV-2 cross-infection. illness [1] . The American Society of Transplantation recommends performing living kidney transplantation only under acceptable conditions [2] . Our patient had a negative COVID-19 PCR test result during the retest, and symptoms had resolved. Moreover, the initial SARS-CoV-2 infection occurred between 21 and 90 days before the kidney donation, irrespective of the PCR retest results [2] . Furthermore, a 19-center retrospective study from India reported 31 cases of living donor kidneys from COVID-19-positive donors. For organ donation, the patient must exhibit a full recovery from symptoms at least 28 days before donation and should have tested negative by PCR twice, including immediately before surgery [3] . The COVID-19 PCR-negative status of the donor was confirmed before surgery, and he tested negative for COVID-19 approximately 60 days after symptom onset. Thereafter, we examined if the patient was a stable candidate for kidney transplantation surgery after COVID-19. Complete recovery from COVID-19 symptoms and a positive SARS-CoV-2 IgG antibody test result are prerequisites for qualifying as a kidney transplant candidate [3] . In most patients, SARS-CoV-2 becomes undetectable 10−20 days after the symptoms disappear [4] [5] . Our patient underwent living kidney transplantation 2 months after complete recovery from COVID-19. Cases of a direct donor to recipient COVID-19 transmission have not been reported in the literature. In addition, the time required for definite viral clearance in COVID-19 remains unknown. Living kidney transplantation was safely performed in a patient with COVID-19, without postoperative complications or rejection. During the COVID-19 pandemic, the possibility of SARS-CoV-2 infection during transplantation surgery must be considered. Successful kidney transplantation after COVID-19 2019-nCoV): Recommendations and Guidance for Organ Donor Testing Renal transplantation after recovery from COVID-19 -a case report with implications for transplant programs in the face of the ongoing corona-pandemic Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection Viral dynamics in mild and severe cases of COVID-19 The authors would like to thank Editage (www.editage.jp) for English language editing. The authors declare no conflicts of interest. Informed consent: Written informed consent was obtained from the patient for publication of this case report and accompanying images.Registry and the registration no. of the study/trial: Not applicable.